Granted Patent
B2
US 12,611,443 · App. 17/346,480 · Granted Apr 28, 2026
Methods and compositions related to therapeutic peptides for cancer therapy
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Embodiments of the current invention provide a solution to the problems associated with balancing patient toxicity with broad efficacy of cancer therapy. In particular, embodiments are directed to anti-cancer peptides that demonstrate a broad anti-cancer efficacy with a limited toxicity to normal or non-cancer cells.
Claims (6)
1 . A method for treating cancer comprising administering an effective amount of a therapeutic composition comprising a peptide selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5, to a subject having cancer, wherein the cancer is breast cancer, melanoma or lung cancer, wherein the therapeutic composition is administered by injection.
2 . The method of claim 1 , further comprising administering a second anticancer therapy, wherein the second anticancer therapy is a chemotherapy, radiotherapy, immunotherapy, or anti-hormonal therapy.
3 . The method of claim 1 , further comprising administering a second anticancer therapy, wherein the second anticancer therapy is an ELANE protease.
4 . The method of claim 1 , wherein the peptide is SEQ ID NO:3.
5 . The method of claim 1 , wherein the peptide is SEQ ID NO:4.
6 . The method of claim 1 , wherein the peptide is SEQ ID NO:5.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 9, 2021
From: BECKER, LEV; CUI, CHANG
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 056803/0720 →
Continuity (3)
Continuation
PCTUS2019067890
· Dec 20, 2019
Provisional Application
62782690
· Dec 20, 2018
References Cited (50)
US 9850308B2
· Martin-Villalba et al.
· 2017
[cited by applicant]
US 20120183552A1
· Joseloff et al.
· 2012
[cited by applicant]
WO WO2000069897
· 2000
[cited by applicant]
WO WO2008067305
· 2008
[cited by applicant]
WO WO2014060848
· 2014
[cited by applicant]
WO WO2014118643
· 2014
[cited by applicant]
WO WO2016166521
· 2016
[cited by applicant]
WO WO2018073394
· 2018
[cited by applicant]
WO WO2018232273
· 2018
[cited by applicant]
WO WO2019051001
· 2019
[cited by applicant]
Bruno et al [Ther Deliv, Nov. 2013, 4(11), 1443-1467] (Year: 2013).
[cited by examiner]
Bowie et al (Science, 1990, 247:1306-1310) (Year: 1990).
[cited by examiner]
Burgess et al (J. Cell Biol. 111:2129-2138, 1990) (Year: 1990).
[cited by examiner]
Lazar et al (Mol. Cell. Biol., 8:1247-1252, 1988) (Year: 1988).
[cited by examiner]
Chen et al., “CD95 promotes tumour growth” Nature 2010, 465(7297), 492-496.
[cited by applicant]
Extended European Search Report issued in Corresponding European Application No. 19899959.1, dated Jul. 21, 2022.
[cited by applicant]
Raghava et al., “Quantification of the variation in percentage identity for protein sequence alignments”
[cited by applicant]
Office Action issued in corresponding Chinese Application No. 201980092976.7, dated Aug. 26, 2023.
[cited by applicant]
Chen et al., “Sugar transporters for intercellular exchange and nutrition of pathogens”
[cited by applicant]
Coffelt et al., “IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis”
[cited by applicant]
Coffelt et al., “Neutrophils in cancer: neutral no more”
[cited by applicant]
Dancey et al., “Neutrophil kinetics in man.”
[cited by applicant]
Eruslanov et al., “Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap”
[cited by applicant]
Finisguerra et al., “MET is required for the recruitment of anti-tumoural neutrophils”
[cited by applicant]
Hadji et al., “Death Induced by CD95 or CD95 Ligand Elimination”
[cited by applicant]
Houghton et al., “Neutrophil Elastase-Mediated Degradation of IRS-1 Accelerates Lung Tumor Growth”
[cited by applicant]
International Search Report and Written Opinion issued in Corresponding PCT Application No. PCT/US2019/067890, dated Mar. 24, 2020.
[cited by applicant]
Kruger et al., “Neutrophils: Between Host Defence, Immune Modulation, and Tissue Injury”
[cited by applicant]
Martin-Villalba et al., “CD95 in cancer: tool or target?”
[cited by applicant]
Murmann et al., “Induction of DISE in ovarian cancer cells in vivo”
[cited by applicant]
Nathan, C. “Neutrophils and immunity: challenges and opportunities”
[cited by applicant]
Ngwa et al., “Using immunotherapy to boost the abscopal effect”
[cited by applicant]
Peter et al. “The role of CD95 and CD95 ligand in cancer,”
[cited by applicant]
Pham, Christine T. N. “Neutrophil serine proteases: specific regulators of inflammation”
[cited by applicant]
Powell et al., “Neutrophils in the Tumor Microenvironment”
[cited by applicant]
Sagiv et al., “Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer”
[cited by applicant]
Shen et al., “Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis”
[cited by applicant]
Strand et al., “Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells”
[cited by applicant]
Yan et al., “Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells”
[cited by applicant]
Young et al., “Mechanism of membrane damage mediated by human eosinophil cationic protein”
[cited by applicant]
Choi et al., “Predicting the Functional Effect of Amino Acid Substitutions and Indels,” Plos One, 7(10):e46688, pp. 1-13, 2012.
[cited by applicant]
Dehouck et al., “Fast and accurate predictions of protein stability changes upon mutations using statistical potentials and neural networks: PoPMuSiC-2.0,” BioInformatics, 25(19)2537-2543, 2009.
[cited by applicant]
Guo et al., “Protein tolerance to random amino acid change,” PNAS, 101(25):9205-9210, 2004.
[cited by applicant]
Matthews, “Structural and Genetic Analysis of Protein Stability,” Annu. Rev. Biochem., 62:139-60, 1993.
[cited by applicant]
Ng and Henikoff, “Predicting the Effects of Amino Acid Substitutions on Protein Function,” Annu. Rev. Genomics. Hum. Genet., 7:61-80, 2006.
[cited by applicant]
Teng et al., “Sequence feature-based prediction of protein stability changes upon amino acid substitutions,” BMC Genomics, 11(Suppl. 2):S5, pp. 1-8, 2010.
[cited by applicant]
Teng et al., “Structural Assessment of the Effects of Amino Acid Substitutions on Protein Stability and Protein-Protein Interaction,” Int. J. Comput. Biol. Drug Des., 3(4):334-349, 2010.
[cited by applicant]